Advanced Science. Uncovering Risk.
Matching patients to optimal treatments through molecular age signatures
Clinicians often use a patient’s age to inform treatment decisions in a wide range of clinical scenarios. However, chronological age is an unreliable predictor of individual’s risk of disease of treatment-related adverse outcomes. An individual’s rate of aging is strongly influenced by environmental, genetic, and lifestyle factors which are not accounted for by chronological age alone. In contrast, biomarkers of molecular age provide a snapshot of the overall health and resiliency of the body, helping physicians to better know their patients and more accurately predict their health risks.
How we think of aging
P16 Testing:
Expression of p16 aging biomarker is a powerful predictor of patients physiologic reserve and is being clinically validated in multiple clinical settings.
AKI-Sapere:
AKI-SapereTM, is being clinically validated in a cardiovascular disease setting to identify patients at high risk for acute kidney injury, adverse cardiac outcomes, rehospitalization and death.
Become a Partner
HealthSpan Dx is seeking partnerships with clinicians, pharma companies, and academic researchers that would benefit from our expertise in measuring molecular age signatures in patients across various diseases to uncover patient risk.
